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INTRODUCTION
Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive disorder of motile 
cilia associated with respiratory distress in term neonates, chronic oto-sino-pulmonary 
disease, male infertility, and organ laterality defects in ~50% of cases (1-4). This syndrome 
was initially recognized based on the triad of chronic sinusitis, bronchiectasis, and situs 
inversus (Kartagener syndrome) (5) and Afzelius later recognized that these patients had 
“immotile” cilia and defective ciliary ultrastructure (6). Over time, it was recognized that 
most patients had stiff, uncoordinated, and/or ineffective ciliary beat, and “primary ciliary 
dyskinesia” was used to distinguish this ciliary genetic disorder from secondary or acquired 
ciliary defects.
Even though PCD has an estimated incidence of 1 per 10,000–20,000 births, based on 
population surveys of situs inversus and bronchiectasis (7, 8), it is difficult to determine the 
prevalence of PCD in the United States, largely due to sub-optimal diagnostic approaches 
(9). Further, many physicians do not appreciate and recognize the key clinical features, 
particularly in infants and children; however, recent advances in defining the clinical 
phenotype are likely to increase the level of awareness for PCD (10, 11). Moreover, better 
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definition of genotype/phenotype will also facilitate recognition of the early onset and 
severity of clinical disease in children with PCD (2, 4, 11, 12).
Laboratory diagnostic capabilities have recently benefited from the development of nasal 
nitric oxide (nNO) as a new test for PCD (13). Analysis of ciliary ultrastructure is 
improving; however, we now recognize that ~30% of PCD patients have normal ciliary 
electron micrographs (EMs), which precludes diagnosis by ciliary EMs. Genetic testing is 
also becoming feasible, as there are now 35 genes with PCD-causing genetic mutations (14, 
15), which likely accounts for ~70% of PCD.
There are no validated PCD-specific therapies, and the treatment of PCD has not been 
standardized; however, recently published PCD Foundation consensus recommendations on 
diagnosis, monitoring, and treatment of PCD provide guidelines for clinical care (15).
This article provides an overview of the rapidly evolving state-of-the-art for PCD, including 
a focus on the diagnosis and treatment of PCD, and a summary of the progress that promises 
to revolutionize the identification and treatment of patients with PCD (1-4, 11-15).
STRUCTURE AND FUNCTION OF MOTILE CILIA
Cilia are evolutionarily conserved organelles and motile respiratory cilia have a complex (9 
+ 2) axonemal structure to generate functional ciliary motility (16, 17). Motile cilia have 
microtubules comprised of α- and β-monomers of tubulin (17) (Figure 1). Outer and inner 
dynein arms are present along the length of the peripheral microtubules (doublets), and 
contain enzymes for ATP hydrolysis (16, 17). Nexin–dynein regulatory complexes (“nexin 
links”) connect the doublets, and radial spokes connect the doublets to the central pair for 
structural support during cilia bending (18). Mutations in genes necessary for the biogenesis 
of cilia, or genes encoding the axonemal structure and/or functional components of motile 
cilia, can result in PCD.
During early development, each cell in the embryonic ventral node contains a single motile 
cilium. This specialized cilium has 9 peripheral doublets and dynein arms, but lacks the 
central pair of microtubules (9 + 0 axonemal structure) (17). Functionally, this cilium has a 
rotary motion, which drives a vectorial movement and laterality of organ lateralization 
during embryogenesis (19). When nodal ciliary function is absent, organ lateralization is 
random. Mutations in genes that encode for components of the central apparatus (central 
pair, radial spokes) do not cause laterality defects (1, 14, 15).
In addition to motile cilia, most cells of the body have a single nonmotile (sensory or 
primary) cilium that has specialized receptors to sense the local environment, and that play a 
key role in planar cell polarity (20). Mutations in genes encoding proteins for sensory cilia 
cause disorders involving multiple organs (e.g., Bardet- Biedl syndrome, nephronophthisis, 
retinitis pigmentosa, and Joubert syndrome) (20).
The function of normal motile cilia is to clear mucus as well as bacteria and toxic substances 
from the conducting airways (21, 22). ATP hydrolysis in dynein arms induces sliding of 
adjacent axonemal structures, and generates the complex ciliary waveform in human airways 
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(16-18, 23). Several hundred cilia per cell beat in a coordinated fashion, which generates 
coordinated vectorial flow from planar orientation (24). The cilia beat in-plane, and the 
forward (power) stroke is more rapid and extends a bit higher into the mucus layer than the 
recovery stroke (23). Ciliary beating is regulated by multiple signaling molecules, including 
cAMP, cGMP, and NO (16).
ULTRASTRUCTURAL AND FUNCTIONAL DIAGNOSTIC TESTS
The diagnosis of PCD is delayed in both European and North American children (median 
age of diagnosis, 5.5 yrs. and 5.0 yrs., respectively) (1). Since most institutions do not have 
adequate resources for a rigorous diagnostic evaluation for PCD, referral to specialized 
centers may be beneficial. This certainly includes patients with situs inversus with any 
respiratory disease, or unexplained neonatal respiratory distress, as well as bronchiectasis 
without a defined etiology, and/or a family history of PCD. For adults, all males with 
abnormal spermatozoal movement should be evaluated for PCD, if they have respiratory 
symptoms. Several medical disorders and phenotypes may coexist with PCD, including 
complex congenital heart disease, laterality defects, retinitis pigmentosa, hydrocephalus, 
pectus excavatum, and scoliosis (1-4).
In the evaluation of patients with chronic respiratory disease, it is critical to identify 
phenotypic features that characterize PCD, as compared with other diseases (11, 15). 
Neonatal respiratory distress is a common feature (> 80%) and a useful marker of PCD 
(Table 1), particularly for infants or children who have not developed bronchiectasis, and 
represent special challenge for diagnosis (11, 15, 25, 26). Laterality defects are relatively 
specific for distinguishing children with PCD from other children with chronic respiratory 
symptoms. The early onset and persistence of respiratory symptoms may help distinguish 
PCD from disorders with more episodic respiratory symptoms (11, 12, 15). In PCD, the 
chronic nasal congestion and wet cough occur on a daily basis throughout the year. Chronic 
otitis media often appears in the first months of life, and is persistent, despite antibiotics 
and/or use of tympanostomy tubes (11, 12). If bronchiectasis is identified in a young child, 
and CF has been ruled out, PCD is highly likely (25-27). In summary, the typical clinical 
phenotype in PCD includes (1) neonatal respiratory distress, and/or (2) chronic, persistent 
lower respiratory symptoms (early onset and persistent wet cough), and/or (3) chronic, 
persistent upper respiratory symptoms (nasal congestion and otitis media), and/or (4) a 
laterality defect (situs inversus or ambiguus) (Table 1). Indeed, the presence of any two of 
these four hallmark clinical features provides a strong clinical phenotype for PCD, assuming 
that CF has been excluded (11, 15).
Electron microscopy (EM) to identify ciliary ultrastructural defects historically has been the 
test used to confirm a diagnosis of PCD, but this approach is no longer the sole “gold 
standard” for diagnosis, since at least 30% of PCD patients have normal ultrastructure (1-4, 
14, 15). For PCD patients with ultrastructural defects, the majority involve the absence or 
shortening of outer dynein arms (ODAs; 38.5%), or an ODA defect in conjunction with an 
inner dynein arm (IDA) defect (10.5%) (Figure 1). Isolated IDA defects occur in only a 
small fraction of confirmed PCD (< 1%), and false-positive EM diagnoses are common with 
IDA defects (9, 28). Before an isolated IDA defect can be used to validate a diagnosis of 
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PCD, a ciliary biopsy for EM must be repeated when the nasal epithelium is healthy (28). 
Most validated IDA defects have associated central apparatus abnormalities (~14% of PCD), 
and these abnormalities occur in only 5–20% of cilia (Figure 1). Central apparatus defects 
associated with IDA defects include microtubular disorganization and transposition of outer 
doublets into the center of cilia cross-sections, and frequently reflect mutations in CCDC39 
or CCDC40 (29, 30). Ciliary “disorientation” (misalignment of the central pair) is a 
secondary change, and is no longer used as a diagnostic ultrastructural feature (31). A few 
patients have absent, or only a few, cilia on multiple biopsies (oligocilia), and recent studies 
show that some of these cases reflect mutations in CCNO or MCIDAS (32, 33). A recent 
report suggested that ultrastructure of respiratory epithelia with “inclusions” of basal bodies, 
and microvilli and cilia, is a variant form of PCD (34), but follow-up studies in several of 
those patients demonstrate that these EM findings are not specific for PCD (personal 
communication, M. Leigh and S. Sagel). The limitations of EM testing of cilia was 
highlighted by the experience in our North American Rare Disease Consortium, where as 
many as 15–20% of the patients referred with a “confirmed” diagnosis of PCD (based on 
ciliary ultrastructure) had a false-positive diagnosis of PCD (35, 36). To optimize the use of 
ciliary EM for diagnosis, many EM cross-sections (multiple sections containing high quality 
images of at least 20 unique cilia), should be examined by experienced readers, using a 
quantitative approach to interpretation (9). EM analysis is more successful in biopsies from 
adults versus children, likely due to limitations in obtaining adequate “scrape” biopsies from 
narrow airways (35, 37). Acquired (secondary) ciliary defects result from airway damage, 
from recurrent infections, and can sometimes be difficult to differentiate from PCD. Finally, 
at least 30% of patients with a strong PCD clinical phenotype and low nNO have normal 
ciliary Ems. For example, a recent study demonstrated that 22% of 61 such patients have 
PCD-causing mutations in DNAH11 (38). Thus, normal ciliary ultrastructure cannot rule out 
PCD.
Evaluations of ciliary motility from fresh biopsies of respiratory epithelium has been used to 
confirm a diagnosis of PCD, particularly in Europe. However, substantial limitations 
preclude reliance on this as the sole diagnostic approach. In this regard, “secondary” effects 
on ciliary function create problems and recognition of more subtle motility defects requires 
experienced investigators (18, 39). It is also now clear that standard light microscopic 
analysis is not sufficient, since many patients with PCD have ciliary movement (40). Even 
with high speed video microscopy (HSVM), there is overlap of ciliary beat frequency 
between PCD and disease control and normal subjects, and there is no standardized protocol 
for interpretation of HSVM (41, 42). There have been multiple approaches to try and 
improve accuracy of HSVM, but these modifications do not eliminate all of the limitations 
(43-45). A recent publication touted the use of “automated” identification of abnormal 
ciliary motion (46), but this approach has not been independently validated, and should not 
be used to diagnose PCD. It is also now clear through genetic testing that many forms of 
PCD have no, or only subtle, abnormalities of ciliary ultrastructure and/or beat frequency 
and waveform. Therefore, these biological assays of ciliary function are not sensitive to 
detecting the growing range of ciliary phenotypes in PCD.
Nasal nitric oxide (nNO) levels in patients with PCD are quite low (<77 nl/min), relative to 
normal values (range 125 to 867 nl/min; mean, 287 nl/min); thus, nNO can be a useful test 
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for PCD if performed correctly (1, 9, 13, 47). Nasal NO is measured by aspirating nasal air 
through a catheter placed at the opening of one nostril and analyzed by an NO analyzer (48). 
Exhaled air from the lower airways has a much lower concentration of NO than the nose; 
thus, maneuvers must be instituted to close the soft palate to limit contamination of nasal air 
by air from the lower airways (48). This approach has been validated in adults and children 
over 5 years of age (13, 49), but is less feasible in younger children. For infants and young 
children, one study measured nNO during tidal breathing (50); however, it should be noted 
that nNO values during tidal breathing are ~40% lower in healthy subjects than values 
obtained at plateau during palate closure. It is critical to recognize that low nNO levels are 
seen in some patients with CF (9, 13, 47). Therefore, CF needs to be ruled out by sweat 
testing or CFTR genetic studies if nNO is low. Because nNO values can be low during acute 
viral infections, acute sinusitis, and panbronchiolitis, measurements should be performed 
when respiratory status is stable, and confirmed on a separate day (1, 13, 15). Although nNO 
has previously been used in a limited number of specialized PCD centers, there is a growing 
number of these specialized Centers in North America (see PCD Foundation website, 
www.pcdfoundation.org). With standardization, and definition of appropriate cut-off values 
(13), nNO measurement is becoming more widely used as a diagnostic test for PCD (Table 
1) (15).
Fluorescence-labeled antibodies have been used to demonstrate absence of cilia axonemal 
and cytoplasmic preassembly proteins, but only a few laboratories are using this approach 
(51, 52). Measurement of mucociliary clearance in the lung has been used in some cases, but 
is not reliable, because it is confounded by involuntary cough and bronchiectasis from other 
etiologies (53). There is no role for the nasal saccharine clearance test as a diagnostic 
method, because of multiple limitations in performance and interpretation of the test.
GENETIC TESTING FOR DIAGNOSIS
PCD is a Mendelian recessive and genetically heterogeneous disorder. Between 1999 and 
2012, PCD-causing mutations were described in 14 genes (1, 2, 4, 14, 15). Since early 2012, 
there has been an explosion of genetic discovery, through exome sequencing, whereby PCD-
causing mutations in 21 additional genes have been published (1, 2, 4, 14, 15) (Table 2). The 
vast majority (81%) of the mutations are loss-of-function changes (nonsense, frameshift, or 
defective splice-sites), and ~19% are conservative missense changes or in-frame del-dup. 
Based on studies of genetic mutations in PCD patients in our North American rare disease 
consortium, and a review of the published literature, it is estimated that ~75% of the 
mutations are private occurring in only one family/patient, but ~25% are seen in multiple 
unrelated families/patients (founder, or recurrent mutations). Mutations in 5 genes (DNAH5; 
DNAH11; DNAI1; CCDC39; CCDC40) are the most prevalent in PCD, and ~26% of these 
mutations are recurrent (14). There are also > 20 mutations that are associated with specific 
ethnic groups or geographical locations (4, 14). It is estimated that ~65-70% of patients with 
PCD can be identified as having two mutations in one of these 35 published PCD genes (14). 
The feasibility of testing a multi-gene panel of PCD genes at a reasonable cost is becoming a 
reality, as several CLIA approved labs and companies have recently begun to offer such 
services (see PCD Foundation website, www.pcdfoundation.org) (15). This type of genetic 
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testing will revolutionize the diagnostic approach in PCD, and lead to early identification 
and initiation of clinical monitoring and treatment.
The role of PCD-associated genes in normal ciliary biogenesis and function, and the effect 
of mutations on cilia structure and function, are detailed in several reviews (1, 2, 4, 14), and 
key points are summarized, here. There is strong correlation between mutations in specific 
genes and effect on ciliary ultrastructure (Table 2). Although most PCD-associated genes 
code for proteins in the ciliary axonemes, there are 10 PCD-associated genes that have a 
functional role in the cytoplasm in “preassembly” of the cilia components, and mutations in 
these genes lead to loss of both ODA and IDA (see Table 2). There is strong correlation 
between mutations in genes that lead to ultrastructural dynein arm defects and the 
development of situs abnormalities, but mutations in genes that code for central apparatus, 
radial spoke, or nexin link proteins are not associated with organ laterality defects. Genetic 
discovery has also provided opportunity to examine ciliary EMs from multiple patients with 
mutations in the same PCD-causing gene, which has allowed recognition of unusual 
changes, such as: 1) radial spoke genes, where as many as 80% of ciliary EM cross-sections 
are normal; and 2) IDA defects associated with microtubular disorganization, which may 
affect only 10% of ciliary cross-sections, and reflect mutations in CCDC39 and CCDC40 
(29, 30). Except for RSPH1 (54) (see below) biallelic loss-of-function mutations routinely 
lead to low nNO (<77 nl/min) (13). Pathogenic mutations in DNAH11 in patients with PCD 
with normal ciliary ultrastructure provides confirmation that PCD can occur in the absence 
of ciliary EM defects (38). Finally, the ciliary beat frequency in patients with mutations in 
some genes (e.g., DNAH11, RSPH4A, RSPH9, RSPH1) with mostly normal EMs can be 
normal (or higher than normal), and the waveforms can appear normal, or have only subtle 
defects (14).
Identification of genetic etiologies of PCD has uncovered unique genotype/phenotype 
relationships. PCD patients with mutations in RSPH1 have milder disease with less neonatal 
respiratory distress (NRD; 50% versus usual 80%), later onset of clinical symptoms, subtle 
EM defects and changes in ciliary waveform, better FEV1 (% Pred.) versus age-and gender-
matched PCD patients with axonemal defects, and borderline (or normal) nasal NO levels 
(54, 55). The milder disease is thought to reflect some residual ciliary function associated 
with a partially intact radial spoke system (55). In contrast, PCD patients with mutations in 
CCDC39 or CCDC40 have more severe disease with a higher prevalence of neonatal 
respiratory distress, earlier onset and severity of clinical symptoms, lower BMI and worse 
FEV1 than other PCD patients, as well as a greater extent of bronchiectasis (56). The 
mechanism of worse disease with mutations in CCDC39 and CCDC40 is not known, 
although we speculate that these genes may play some role in lung host defense that extends 
beyond ciliary function.
EARLY FEATURES OF CLINICAL DISEASE
The clinical features of PCD reflect defective function of motile cilia in the conducting 
airways, paranasal sinuses, middle ear (eustachian tube), and the reproductive tract, as well 
as specialized motile cilia in the ventral node during embryogenesis (1-4) (Table 1). 
Manifestations of PCD occur early in life, and the clinical phenotype gives strong insight 
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about the likelihood of PCD, based on systematic analysis of patients in our rare disease 
consortium (11).
The earliest manifestations of PCD occur in the neonatal period, as > 80% of full-term PCD 
neonates have respiratory distress. Signs include tachypnea and increased work of breathing, 
and affected individuals typically require supplemental oxygen for a few hours to weeks (12, 
57). These infants are often diagnosed with transient tachypnea of the newborn or neonatal 
pneumonia, but the clinical presentation in PCD is quite different with: 1) later onset of 
respiratory distress (12 hours of age); 2) longer duration of required oxygen therapy; and 3) 
higher frequency of atelectasis and/or lobar collapse (57). This neonatal presentation of 
respiratory distress indicates that normal ciliary function plays a critical role in the clearance 
of fetal lung fluid at birth, although the mechanism is unknown. Unexplained respiratory 
distress and radiographic abnormalities, along with supplemental oxygen requirements in a 
full-term infant, should raise suspicion for PCD, particularly in neonates with situs inversus.
Infants and children with PCD typically have year-round wet cough and daily nasal 
congestion (rhinitis) starting soon after birth (1-4, 11). Chronic otitis media that causes 
temporary or permanent hearing loss and recurrent sinusitis are common. Sinusitis is 
sometimes not recognized in young children because radiographic imaging is not performed. 
Bronchiectasis occurs in some infants and preschoolers (12, 25-27). Chest computed 
tomography (CT) scans show various abnormalities, including atelectasis, mucus plugging, 
air trapping, and thickened airway walls (26, 27, 58). These respiratory manifestations 
overlap with other common early childhood diseases; thus, the diagnosis of PCD is 
frequently missed, despite the presence of typical clinical features, even when situs inversus 
is present. This lack of recognition of cardinal clinical features in PCD highlights the 
importance of education for many pertinent subspecialties, including neonatology, 
pulmonology, otolaryngology, and cardiology, as well as primary care.
LUNG DISEASE
Nearly all infants and children with PCD have a year-round daily wet cough, which 
compensates, in part, for defective mucociliary clearances. Despite the daily cough, 
infections occur in the lower airways, and there is age-dependent development of 
bronchiectasis, which is universal in adults with PCD (1, 12, 25, 47, 58).
Respiratory bacteriology of children with PCD is dominated by Haemophilus influenza, 
Staphylococcus aureus, and Streptococcus pneumonia (12). Unlike CF, children with PCD, 
including infants/preschoolers, also intermittently culture Pseudomonas aeruginosa, which 
evolves into chronic airway infection in teenagers and young adults with PCD (12, 47, 59). 
Many patients culture more than one type of bacteria in the same sample. Nontuberculous 
mycobacteria (NTM) are present in 15% of adults with PCD, but there is a lower prevalence 
in children (1, 15, 47).
In contrast to the perceptions of many clinicians, the severity of lung disease in children with 
PCD is substantial. Abnormal lung function develops early in life, as many infants and 
young children demonstrate abnormal airflow mechanics (60-63). The range of FEV1 in 
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PCD is quite heterogeneous at age 6–8 years, as some young PCD patients have obstructive 
airways disease that is worse than patients with CF at the same age. PCD patients have 
evidence of airflow obstruction in “small airways” (i.e., decreased maximum midexpiratory 
flow) and ventilation inhomogeneity, as measured through multiple breath washout (60-64). 
Cross-sectional and longitudinal data show that airflow obstruction worsens with increasing 
age (61-63). However, airways disease does not progress as rapidly in late childhood and 
early adulthood compared with CF, which may relate to preservation of cough clearance. 
One longitudinal study demonstrated that lung function remains stable in PCD patients who 
received regular monitoring and treatment (62).
Radiographic studies utilizing high-resolution chest CT show that lung disease in PCD 
begins in infancy or early childhood. Findings include subsegmental atelectasis, mucus 
plugging, air trapping, ground-glass opacity, and peribronchial thickening. Bronchiectasis 
can occur during infancy, and ~50–75% of older pediatric patients and nearly all adults with 
PCD have bronchiectasis with worse disease in the middle lobe and lingula, as well as 
basilar regions (25-27, 49, 58). Chest CT is more sensitive for detecting early lung disease in 
PCD, compared to lung function testing by spirometry (60). Magnetic resonance imaging of 
the chest may be as effective as chest CT in defining the extent and severity of lung disease 
in PCD, which is an intriguing option for longitudinal evaluation and research (65).
NONPULMONARY MANIFESTATIONS
Situs abnormalities are present in > 50% of pediatric patients, which may aid earlier 
recognition of PCD. Laterality defects reflect abnormal function of the specialized (9 + 0) 
motile cilium during embryogenesis (19). At least 12% of PCD patients have situs 
ambiguous, and these patients have a 200-fold increased probability of having structural 
congenital heart disease compared with the general population with heterotaxy (66-68). 
Indeed, some patients with situs ambiguous have heterotaxia syndromes, which include 
polysplenia (left isomerism) and asplenia (right isomerism). Taken together, these clinical 
characteristics demonstrate a strong association between defective cilia and congenital heart 
disease. Patients with heterotaxy and congenital heart disease have increased respiratory 
complications after cardiac surgery, which suggests that some of these patients may have 
PCD (69, 70). Studies in mice with mutations in motile cilia confirm that cilia are required 
for normal heart development (71).
Almost all men with PCD are infertile, secondary to dysmotility of spermatozoa, or rarely, 
azoospermia. A few men with PCD have adequate sperm motility and have fathered children 
(72). Females with PCD have impaired ciliary function in the fallopian tubes, which may 
lead to reduced fecundity and/or a history of ectopic pregnancies (73).
Pectus excavatum occurs in as many as 10% of patients with PCD, versus 0.3% in the 
general population (58). We and others have also reported a high prevalence of scoliosis (5–
10%) in PCD (1); thus, PCD should be considered in patients with pectus excavatum and/or 
scoliosis and unexplained sinopulmonary disease.
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MANAGEMENT OF LUNG DISEASE
Respiratory symptoms and lung disease in PCD begin early in life, and reflect defective 
mucociliary clearance, which is the key innate pulmonary defense mechanism (21). No 
validated PCD-specific therapies are available; therefore, therapies for PCD are extrapolated 
from other disease, such as cystic fibrosis and non-CF bronchiectasis, particularly as relates 
to antibiotic therapy and macrolides as anti-inflammatory agents (15, 74-78). A recent state-
of-the-art publication provides consensus recommendations from the PCD Foundation for 
monitoring and management of lung disease in PCD (15). Clinic visits at least twice per year 
are recommended for monitoring lung function and respiratory microbiology, including 
NTM. Chest imaging studies are also indicated to periodically monitor the extent of disease. 
Preventive measures include infection control training and routine immunizations, as well as 
pneumococcal and influenza vaccines.
Multiple studies demonstrate that systemic antibiotics are effective at treating worsening 
respiratory symptoms (“exacerbations”) in CF and non-CF bronchiectasis, including some 
patients with PCD (76). Antibiotics should be chosen based on respiratory cultures. 
Unexpectedly, preliminary studies of inhaled antibiotics in non-CF bronchiectasis did not 
show benefit with respect to lung function, although there was a reduction of neutrophil 
elastase activity in sputum in some studies (78, 79). One controlled study (12-months long) 
of inhaled gentamicin in non-CF bronchiectasis demonstrated striking reduction in 
frequency of exacerbations, as well as reductions in the burden of bacteria and markers of 
pulmonary and systemic inflammation (80). It is noteworthy that one study in patients with 
non-CF bronchiectasis demonstrated high rates of eradication for patients who develop 
airway infection with P. aeruginosa (75).
Stimulation of chloride (and liquid) secretion by an inhaled P2Y2 receptor agonist has been 
reported to improve cough clearance of radiolabeled particles in a small study of adults with 
PCD (81). More recently, nebulized 7% hypertonic saline improved lung function and 
quality of life, and reduced antibiotic use in non-CF bronchiectasis in a three month study 
(82). The therapeutic concept is that stimulation of cough and increased hydration of airway 
secretions with hypertonic saline (or other osmotic agents) can benefit cough clearance. By 
analogy, hydrating airway secretions may benefit cough clearance in PCD, even though 
defective mucociliary clearance persists. Dornase alfa has not been shown to improve 
pulmonary status in non-CF bronchiectasis, even though it is beneficial in CF. Indeed, adults 
with non-CF bronchiectasis taking dornase alfa for 24 weeks experienced more pulmonary 
exacerbations and a greater decline in FEV1 compared with the placebo group (83).
Oral macrolides are clearly effective in CF through anti-inflammatory mechanisms, resulting 
in improvement in lung function and reduction in exacerbations. In non-CF bronchiectasis, 
similar data are emerging in small studies in regards to reducing exacerbations (74, 77). In 
contrast to CF, most patients with non-CF bronchiectasis have bacterial infections other than 
P. aeruginosa; therefore, the mechanism of action for macrolides in non-CF bronchiectasis 
could relate, in part, to antibiotic effect. PCD patients should not receive chronic oral 
macrolides unless they have been tested and shown to not harbor NTM (74, 77). The 
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widespread use of inhaled or systemic corticosteroids in non-CF bronchiectasis has not been 
validated by standardized clinical studies.
Resection of severely affected lung in PCD is occasionally useful, but should be undertaken 
only after careful consideration and consultation with PCD experts, because PCD affects all 
regions of the lung. The selection of patients for resection should focus on those with severe 
localized bronchiectasis and recurrent febrile relapses or severe hemoptysis, despite 
aggressive medical management (84). Patients with end-stage PCD lung disease are 
candidates for lung transplantation, and a modest number of transplants have been 
successfully performed.
Some key goals for the PCD community to develop the requisite capabilities for performing 
therapeutic clinical trials have recently been achieved. Specifically, there is now expanded 
capability to perform genetic testing for the diagnosis of PCD at a reasonable cost, which 
will expand the pool of patients with a confirmed diagnosis of PCD. There is also an 
increasing number of PCD clinical sites to perform those clinical trials. Further, there is a 
published quality-of-life (QOL) instrument as an outcome measure in PCD adults (85) and 
another QOL instrument for pediatric patients is close to being finalized. Therefore, the PCD 
community is poised to do therapeutic studies for lung disease in PCD (see “Future 
Directions” below, and PCD Foundation website, www.pcdfoundation.org).
MANAGEMENT OF OTOLARYNGOLOGIC MANIFESTATIONS
Otitis media with effusion affects almost all children with PCD, but there is no consensus for 
management, even though this disorder has implications for conductive hearing loss, delayed 
speech and language development, and cholesteatoma formation (12, 15, 86). Those who 
support the use of tympanostomy tubes suggest that hearing may be improved long term in 
some patients, and otorrhea can be controlled (86). In contrast, the European Respiratory 
Society Consensus Statement recommends against placement of tubes for chronic otitis 
media in PCD, because resultant otorrhea is problematic, and spontaneous resolution of 
chronic otitis media may occur in the teenage years (87, 88). Acute episodes of otitis media 
should be treated by standard approaches, but the question of surgical intervention remains. 
It should be recognized that chronic otitis media may persist into adulthood, and conductive 
hearing loss (“glue ear”) occurs in some patients. Therefore, audiology assessments, hearing 
aids, and communication assistance should be employed.
Sinus disease is a major problem in PCD. Initial management may include nasal steroids, 
nasal lavage, and intermittent courses of systemic antibiotics. Polyps may require surgery, 
and functional endoscopic sinus surgery is helpful in many patients who are refractory to 
medical therapy, particularly if there is good postsurgical treatment to maintain adequate 
drainage (89, 90).
FUTURE DIRECTIONS
Although treatment of patients with PCD has not been standardized, the recent PCD 
Foundation consensus statement on diagnosis and management offers specific guidance for 
clinicians. It is hoped that this will improve clinical care, including regular surveillance of 
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clinical status, lung function, and respiratory microbiology, and allow antibiotic treatment 
targeted to specific pathogens. A multidisciplinary approach to management of chronic 
disease is well recognized to benefit long-term outcomes, particularly for rare diseases, such 
as CF. The PCD Foundation is developing a national registry, and an ever-growing network 
of certified PCD clinical centers, which should alleviate some of the inconsistency in care. 
This network will also facilitate discovery of additional PCD genes, and allow more 
extensive studies of genotype/phenotype in PCD. Further, this network will also facilitate the 
identification of patients with PCD for participation in prospective clinical trials, and 
provide geographically dispersed sites for these therapeutic trials (see PCD Foundation 
website for further information, www.pcdfoundation.org). In summary, there has been 
striking progress in our understanding of PCD over the past 15 years, and this is being 
rapidly translated into more available and effective clinical care.
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Key points
• Primary ciliary dyskinesia (PCD) is a recessive genetically 
heterogeneous disorder of motile cilia with chronic oto-sino-pulmonary 
disease and organ laterality defects in ~50 of cases.
• The prevalence of PCD is difficult to determine, because there has 
historically been no readily available and standardized diagnostic 
approach.
• Recent diagnostic advances through nasal nitric oxide (nNO) and 
genetic testing has allowed rigorous diagnoses, and determination of a 
strong clinical phenotype, which includes neonatal respiratory distress, 
daily nasal congestion and wet cough starting early in life, along with 
organ laterality defects.
• There is early onset of lung disease in PCD with abnormal airflow 
mechanics and radiographic abnormalities detected in infancy and early 
childhood.
• The treatment of PCD is not fully standardized, but PCD Foundation 
Consensus recommendations on diagnosis, monitoring, and treatment 
of PCD have recently been published.
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Figure 1. 
Ciliary ultrastructure. (A) Schematic of cross-section of cilium with 9 + 2 configuration. 
Ciliary ultrastructure by electron micrographs (EMs) from (B) normal subject and (C-G) 
patients with primary ciliary dyskinesia (PCD). (A) The 9 + 2 structure is shown with 
individual components of the axonemal structure. (B) Normal EM. (C) ODA defect, as seen 
in DNAH5 mutations. (D) ODA + IDA defect, as seen in DNAAF1 mutations. (E-F) IDA 
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defect alone, and IDA defect with microtubular disorganization, as seen in CCDC39 
mutations. (G) Missing central pair, as seen in ~12% of cilia with RSPH1 mutations.
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